Literature DB >> 24913710

Relationships between VEGF protein expression and pathological characteristics of diffuse large B cell lymphoma: a meta-analysis.

Lu Sui1, Kun Liu, Wei Shen, Liang Zhang.   

Abstract

We carried out the current meta-analysis of relevant cohort studies in an attempt to investigate the relationships between vascular endothelial growth factor (VEGF) expression and pathological characteristics of diffuse large B cell lymphoma (DLBCL). The following electronic databases were searched for relevant articles without any language restrictions: Web of Science (1945 ~ 2013), the Cochrane Library Database (Issue 12, 2013), PubMed (1966 ~ 2013), EMBASE (1980 ~ 2013), CINAHL (1982 ~ 2013), and the Chinese Biomedical Database (CBM) (1982 ~ 2013). Meta-analyses were conducted with the use of STATA software (version 12.0, Stata Corporation, College Station, TX, USA). Odds ratios (ORs) and its 95 % confidence interval (95 % CI) were calculated. Nine clinical cohort studies with a total of 789 DLBCL patients met our inclusion criteria. The meta-analysis results showed that patients with positive VEGF expression had higher international prognostic index (IPI) scores than VEGF-negative patients (OR = 5.12, 95 % CI = 2.70 ~ 9.71, P < 0.001). There was a significantly positive association between positive VEGF expression and evaluated lactate dehydrogenase (LDH) levels (OR = 2.50, 95 % CI = 1.36 ~ 4.60, P = 0.003). We also found that patients with positive B symptoms had increased level of VEGF expression (OR = 2.02, 95 % CI = 1.08 ~ 3.77, P = 0.027). The findings of our meta-analysis provide reliable evidence that VEGF expression may be strongly correlated with pathological characteristics of DLBCL.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24913710     DOI: 10.1007/s13277-014-2173-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

1.  Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis.

Authors:  Yingdi Wang; Masanori Nakayama; Mara E Pitulescu; Tim S Schmidt; Magdalena L Bochenek; Akira Sakakibara; Susanne Adams; Alice Davy; Urban Deutsch; Urs Lüthi; Alcide Barberis; Laura E Benjamin; Taija Mäkinen; Catherine D Nobes; Ralf H Adams
Journal:  Nature       Date:  2010-05-27       Impact factor: 49.962

2.  Plasma concentrations of vascular endothelial growth factor and basic fibroblast growth factor in lymphoproliferative disorders.

Authors:  Lukás Smolej; Ctirad Andrýs; Vladimír Maisnar; Ludĕk Pour; Jaroslav Malý
Journal:  Acta Medica (Hradec Kralove)       Date:  2005

3.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.

Authors:  Olivier Keunen; Mikael Johansson; Anaïs Oudin; Morgane Sanzey; Siti A Abdul Rahim; Fred Fack; Frits Thorsen; Torfinn Taxt; Michal Bartos; Radovan Jirik; Hrvoje Miletic; Jian Wang; Daniel Stieber; Linda Stuhr; Ingrid Moen; Cecilie Brekke Rygh; Rolf Bjerkvig; Simone P Niclou
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

Review 4.  Pathways mediating VEGF-independent tumor angiogenesis.

Authors:  Napoleone Ferrara
Journal:  Cytokine Growth Factor Rev       Date:  2009-12-11       Impact factor: 7.638

Review 5.  Prognostic [corrected] significance of angiogenic/lymphangiogenic, anti-apoptotic, inflammatory and viral factors in 88 cases with diffuse large B cell lymphoma and review of the literature.

Authors:  Semra Paydas; Melek Ergin; Gulsah Seydaoglu; Seyda Erdogan; Sinan Yavuz
Journal:  Leuk Res       Date:  2009-03-16       Impact factor: 3.156

Review 6.  Diffuse large B-cell lymphoma.

Authors:  Maurizio Martelli; Andrés J M Ferreri; Claudio Agostinelli; Alice Di Rocco; Michael Pfreundschuh; Stefano A Pileri
Journal:  Crit Rev Oncol Hematol       Date:  2013-01-30       Impact factor: 6.312

7.  Pretreatment levels of vascular endothelial growth factor in plasma predict a complete remission rate and time to relapse or progression in patients with diffuse large B-cell lymphoma.

Authors:  Ewa Lech-Maranda; Jacques Bienvenu; Florence Broussais-Guillaumot; Anne-Sophie Michallet; Krzysztof Warzocha; Przemysław Biliński; Peter Boyle; Bertrand Coiffier; Gilles Salles
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2013-01-03       Impact factor: 4.291

8.  Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).

Authors:  Dita Gratzinger; Ranjana Advani; Shuchun Zhao; Neha Talreja; Robert J Tibshirani; Ragini Shyam; Sandra Horning; Laurie H Sehn; Pedro Farinha; Javier Briones; Izidore S Lossos; Randy D Gascoyne; Yasodha Natkunam
Journal:  Br J Haematol       Date:  2009-10-11       Impact factor: 6.998

9.  Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer.

Authors:  B K Linderholm; H Hellborg; U Johansson; G Elmberger; L Skoog; J Lehtiö; R Lewensohn
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

10.  Profile of time-dependent VEGF upregulation in human pulmonary endothelial cells, HPMEC-ST1.6R infected with DENV-1, -2, -3, and -4 viruses.

Authors:  Azliyati Azizan; Kelly Fitzpatrick; Aimee Signorovitz; Richard Tanner; Heidi Hernandez; Lillian Stark; Mark Sweat
Journal:  Virol J       Date:  2009-05-06       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.